The MAPP research network: design, patient characterization and operations

BMC Urology

Table 2 Number of participants (target, enrolled) by cohort, sex (UCPPS: duration of symptoms), and number of participants with biospecimens by type, MRI scans completed and PPT data collected at baseline visit

Cohorts	No. of participants by cohort		No. of participants with biospecimens						No. of participants with MRI scans	No. of Participants with Pain Pressure Threshold (PPT) measures
	Target size	Actual enrolled	Cheek swab	Biomarker samples		Infectious etiology urine samples				At baseline	During follow-up
	Target size	Actual enrolled	Cheek swab	Plasma	Urine	VB1	VB2	VB3		At baseline	During follow-up
UCPPS (Duration of symptoms)
*Male < 2 Yrs*	95	90	90	90	90	90	90	39	13	19	20
*Male ≥ Yrs*	95	101	100	100	101	100	100	42	22	12	20
*Female < 2 Yrs*	95	89	89	86	89	89	88	0	22	20	19
*Female ≥2 Yrs*	95	144	144	142	144	142	139	0	41	11	23
Total	380	424	423	418	424	421	417	81	98	62	82
Healthy controls
*Male*	190	182	182	177	181	176	174	64	38	40	0
*Female*	190	233	233	228	232	232	227	0	79	60	0
Total	380	415	415	405	413	408	401	64	117	100	0
Positive controls
*Male*	95	44	44	43	43	43	43	10	17	8	0
*Female*	95	156	156	154	154	154	152	0	47	27	0
Total	190	200	200	197	197	197	195	10	64	35	0
Overall total	950	1,039	1,038	1,020	1,034	1,026	1,013	155	279	197	82

ISSN: 1471-2490